Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 615-624

  Yamamoto, Sohei ^a   Tsuda, Hitoshi ^b   Takano, Masashi ^a   Tamai, Seiichi ^c   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

Author keywords

ARID1A; clear cell adenofibroma; clear cell carcinoma; endometriosis; PIK3CA

Indexed keywords

GENOMIC DNA;

ADULT; ARTICLE; AT RICH INTERACTIVE DOMAIN 1A GENE; BENIGN TUMOR; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; DNA SEQUENCE; ENDOMETRIOSIS; EXON; FEMALE; FIBROMA; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OVARY CARCINOMA; PIK3CA GENE; PRECURSOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADENOFIBROMA; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; ENDOMETRIOSIS; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MUTATION; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859427109     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.189     Document Type: Article

References (36)

1. Lee KR, Tavassoli FA, Part J, et al. Surface epithelialstromal tumours. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 117-145.
2. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376.
3. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94:138-143. (Pubitemid 44267195)
4. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-1374. (Pubitemid 43772268)
5. Fukunaga M, Nomura K, Ishikawa E, et al. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997;30: 249-255. (Pubitemid 27148154)
6. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006;119:556-562. (Pubitemid 43955708)
7. Yamamoto S, Tsuda H, Takano M, et al. Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol 2008;21:115-124. (Pubitemid 351172160)
8. Yamamoto S, Tsuda H, Miyai K, et al. Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology 2010;56:740-749.
9. Yamamoto S, Tsuda H, Takano M, et al. Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol 2008;216:103-110.
10. Veras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 2009;33:844-853.
11. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
12. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-1543.
13. Jones S, Wang TL, Shih I, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-231.
14. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-1601.
15. Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011;225:189-194.
16. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-1668.
17. Sif S, Saurin AJ, Imbalzano AN, et al. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 2001;15: 603-618. (Pubitemid 32205148)
18. Wang W, Xue Y, Zhou S, et al. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 1996;10:2117-2130. (Pubitemid 26303868)
19. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 2010;463:474-484.
20. Gao X, Tate P, Hu P, et al. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci USA 2008;105:6656-6661. (Pubitemid 351754562)
21. Huang J, Zhao YL, Li Y, et al. Genomic and functional evidence for an ARID1A tumour suppressor role. Genes Chromosomes Cancer 2007;46:745-750. (Pubitemid 46912345)
22. Nagl Jr NG, Patsialou A, Haines DS, et al. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 2005;65:9236-9244. (Pubitemid 41507989)
23. Nagl Jr NG, Zweitzig DR, Thimmapaya B, et al. The c-myc gene is a direct target of mammalian SWI/SNFrelated complexes during differentiation-associated cell cycle arrest. Cancer Res 2006;66:1289-1293. (Pubitemid 43259906)
24. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102. (Pubitemid 29036292)
25. Samuels Y,Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
26. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-807. (Pubitemid 40282746)
27. Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010;11:5120-5128.
28. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011;35: 625-632.
29. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-363.
30. Medina PP, Romero OA, Kohno T, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008;29:617-622. (Pubitemid 351614585)
31. Rodriguez-Nieto S, Canada A, Pros E, et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum Mutat 2010;32:E1999-E2017.
32. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011;224:328-333.
33. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007;2:57-85. (Pubitemid 46448060)
34. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-10673. (Pubitemid 41713332)
35. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-Ras alterations. Hum Pathol 2006;37:1465-1472.
36. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5935. (Pubitemid 44703751)